<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Chronic thromboembolic pulmonary hypertension: Pulmonary hypertension-specific therapy
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter F Fedullo, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jess Mandel, MD, MACP, ATSF, FRCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Geraldine Finlay, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 05, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1662726">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary thromboendarterectomy (PTE) is the only potentially curative therapy. However, some patients are not suitable candidates for PTE, have persistent pulmonary hypertension (PH) after PTE, or need a bridge to PTE. In such patients, PH-specific therapy is often administered.
        </p>
        <p>
         PH-specific therapy refers to the use of medications that target the PH itself (ie, pulmonary vasodilators and remodeling agents). These agents lower the pulmonary vascular resistance (PVR) and pulmonary artery pressure with the goal of improving exercise capacity and oxygenation. Importantly, PH-specific therapy is not curative and its effects are relatively modest [
         <a href="#rid1">
          1-4
         </a>
         ].
        </p>
        <p>
         Selecting suitable patients and choosing a PH-specific therapy are reviewed here. The diagnosis of CTEPH and the general approach to assessing patients for PTE are described separately. (See
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8255.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
         The approach outlined in this topic is, for the most part, consistent with guidelines set out by several international societies [
         <a href="#rid3">
          3,5-7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1663229">
         <span class="h1">
          PATIENT SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with chronic thromboembolic pulmonary hypertension (CTEPH), the two most common indications for pulmonary hypertension (PH)-specific therapy are patients with inoperable CTEPH and patients with persistent CTEPH following pulmonary thromboendarterectomy (PTE) or, rarely, following balloon pulmonary angioplasty.
        </p>
        <p>
         The use of PH-specific therapy as a bridge to PTE is an uncommon indication.
        </p>
        <p>
         PH-specific therapy is not administered routinely preoperatively, since it is not of proven benefit and may delay time to referral for surgery [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3431989040">
         <span class="h2">
          Inoperable CTEPH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients may not be operative candidates due to a personal choice, the anatomic distribution of their disease, the extent of their disease, or their comorbidities. The decision that a patient's disease is inoperable should only be made after a comprehensive evaluation at a center with experience in the management of CTEPH  (
         <a class="graphic graphic_algorithm graphicRef131060" href="/z/d/graphic/131060.html" rel="external">
          algorithm 1
         </a>
         ). Further details on the evaluation of patients for PTE are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Evaluation for pulmonary thromboendarterectomy'
         </a>
         .)
        </p>
        <p>
         Data to support this indication are derived from small randomized trials and several observational studies, the details of which are discussed below. (See
         <a class="local">
          'Medication selection'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2734190840">
         <span class="h2">
          Persistent CTEPH
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small proportion of patients have a suboptimal hemodynamic and functional outcome following PTE (15 to 51 percent; on average 30 percent). Many patients in this population are treated with PH-specific therapy. A management strategy for patients with residual PH after PTE that allocates therapy based upon functional status is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/8255.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy", section on 'Residual pulmonary hypertension'
         </a>
         .)
        </p>
        <p>
         Data that support the use of PH-specific therapies in this population are derived from subgroup analyses in randomized trials and observational studies that included patients with both inoperable and persistent CTEPH [
         <a href="#rid9">
          9-11
         </a>
         ]. In these studies, approximately one-third of the study population had persistent CTEPH following thromboendarterectomy. These data are discussed below. (See
         <a class="local">
          'Medication selection'
         </a>
         below.)
        </p>
        <p>
         Variable definitions of persistent PH following PTE have been used with no consensus among experts. While we and others define it as pulmonary vascular resistance (PVR) ≥300 dynes-sec/cm
         <sup>
          -5
         </sup>
         (≥3.75 Wood units), others use a mean pulmonary artery pressure ≥30 mmHg [
         <a href="#rid12">
          12,13
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2983645096">
         <span class="h2">
          Bridge to surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although controversial, we use PH-specific therapy in patients with severe life-threatening CTEPH as a therapeutic bridge to definitive PTE; examples include patients with hemodynamic indices of severe PH and evidence of severe right heart failure [
         <a href="#rid8">
          8,14
         </a>
         ]. In this setting, PH-specific therapy is used as a lifesaving strategy to help patients survive to definitive surgical intervention. There is no single agent that is superior in this setting, although
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         is commonly used. (See
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Medical therapy as a bridge to surgery (not routine)'
         </a>
         and
         <a class="local">
          'WHO functional class IV (severe symptoms)'
         </a>
         below.)
        </p>
        <p>
         Importantly, PH-specific therapy should not be routinely used as a preoperative therapy and, in particular, should not delay appropriate referral for PTE.
        </p>
        <p>
         There are limited data that support this indication, which are discussed in the sections below. (See
         <a class="local">
          'WHO functional class IV (severe symptoms)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3757438">
         <span class="h1">
          MEDICATION SELECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension (PH)-specific therapy should
         <strong>
          only
         </strong>
         be administered at specialized PH centers. The principles of medication selection, administration, and follow-up of patients with chronic thromboembolic pulmonary hypertension (CTEPH; group 4 PH) who receive PH-specific therapy are generally similar to that of patients with group 1 pulmonary arterial hypertension (PAH)  (
         <a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ); the exceptions are that vasoreactivity testing is
         <strong>
          not
         </strong>
         performed, since patients are rarely vasoreactive, and, for those in whom oral therapy is chosen, the drug of choice is
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
         Small randomized trials and observational studies suggest that PH-specific therapy for patients with inoperable or persistent CTEPH has hemodynamic and symptomatic benefits. However, these benefits are modest compared with those that can be achieved with pulmonary thromboendarterectomy (PTE) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Few studies of individual agents have shown improved survival, although one retrospective review of patients with CTEPH reported a similar one- and three-year survival among patients who were medically treated for inoperable CTEPH compared with patients who were surgically treated (82 versus 88 percent; 70 versus 76 percent) [
         <a href="#rid15">
          15
         </a>
         ]. However, these data are fundamentally flawed. Rigorous studies are required before firm conclusions can be made regarding a survival benefit from PH-specific therapy compared with surgical therapy. (See
         <a class="medical medical_review" href="/z/d/html/8255.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy", section on 'Long term outcomes'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H343061274">
         <span class="h2">
          Pre-treatment evaluation
         </span>
        </p>
        <p class="headingAnchor" id="H2719927648">
         <span class="h3">
          Pulmonary artery catheterization without vasoreactivity testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to patients with group 1 PAH, we ensure that patients with CTEPH who are selected for PH-specific therapy have had a recent pulmonary artery catheterization study prior to the initiation of therapy (eg, within a few weeks). Pulmonary artery catheterization has usually been done as part of the initial diagnostic investigation for CTEPH but may need to be repeated if symptoms have progressed since the original diagnosis. (See
         <a class="medical medical_review" href="/z/d/html/8254.html" rel="external">
          "Epidemiology, pathogenesis, clinical manifestations and diagnosis of chronic thromboembolic pulmonary hypertension", section on 'Diagnostic evaluation'
         </a>
         .)
        </p>
        <p>
         Unlike patients with group 1 PAH, vasoreactivity testing prior to the initiation of therapy is
         <strong>
          not
         </strong>
         necessary in patients with CTEPH, because they are rarely vasoreactive [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Vasoreactivity testing (select patients)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1296094305">
         <span class="h3">
          Assess factors that influence agent selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to group 1 PAH, many factors affect agent selection in this population including patient preference, cost, availability, safety, route of administration, and functional class World Health Organization (WHO)  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         and
         <a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">
          table 4
         </a>
         and
         <a class="graphic graphic_table graphicRef123026" href="/z/d/graphic/123026.html" rel="external">
          table 5
         </a>
         ), the details of which are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2859840421">
         <span class="h3">
          Medication options
         </span>
         <span class="headingEndMark">
          —
         </span>
         PH-specific medications used to treat CTEPH were developed to treat patients with group 1 PAH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ). They include parenteral prostanoids (
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         ,
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         ,
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         ), soluble guanylate cyclase stimulants (
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         ), endothelin receptor antagonists (ERAs;
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         ,
         <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">
          ambrisentan
         </a>
         ,
         <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">
          macitentan
         </a>
         ), phosphodiesterase-5 inhibitors (
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ,
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         ), and oral prostanoid agonists (
         <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">
          selexipag
         </a>
         )  (
         <a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H3578539641">
         <span class="h2">
          WHO class I (asymptomatic or minimally symptomatic)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with CTEPH rarely present with WHO functional class I symptoms  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ) since patients in this class are typically asymptomatic. However, in theory, not every patient in this category may need or want therapy. Thus, the decision to initiate PAH-specific therapy should be based on objective hemodynamic parameters to avoid ongoing progression of PH and personal preference. For those who do not receive or decline therapy, we closely observe clinically for PH progression.
        </p>
        <p class="headingAnchor" id="H3733800181">
         <span class="h2">
          WHO class II or III (mild to moderate symptoms)
         </span>
         <span class="headingEndMark">
          —
         </span>
         In most CTEPH patients with WHO functional class II to III symptoms  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ), we initiate monotherapy with an oral agent, typically
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         . This approach is based upon small randomized trials and observational studies that have demonstrated improved exercise capacity, functional class, and pulmonary hemodynamics in patients with CTEPH, among which riociguat has the strongest evidence in favor of a benefit. No robust evidence has suggested a survival benefit. (See
         <a class="local">
          'Choosing an oral agent'
         </a>
         below.)
        </p>
        <p>
         Occasionally, in patients with severe class III symptoms or class III symptoms that are rapidly progressive, we administer a parenteral prostanoid, the details of which are discussed below. (See
         <a class="local">
          'Parenteral prostanoid'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1807126124">
         <span class="h3">
          Choosing an oral agent
         </span>
         <span class="headingEndMark">
          —
         </span>
         In patients with CTEPH who have WHO functional class II to III  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ), we typically administer oral
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         (
         <a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">
          table 1
         </a>
         ), provided that there are no contraindications. Our preference for riociguat is based upon demonstrated efficacy in randomized trials in patients with inoperable CTEPH or persistent CTEPH following surgery as well as a favorable safety profile and our clinical experience with this agent. These data are discussed below. (See
         <a class="local">
          'Riociguat'
         </a>
         below.)
        </p>
        <p>
         As alternatives,
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         (ERA) or
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         (phosphodiesterase inhibitor) are appropriate as oral agents with favorable hemodynamic and safety profiles in patients with CTEPH. If bosentan or sildenafil are not tolerated,
         <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">
          macitentan
         </a>
         and
         <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">
          ambrisentan
         </a>
         (ie, oral ERAs) are additional alternatives [
         <a href="#rid17">
          17,18
         </a>
         ]. These data are discussed below. (See
         <a class="local">
          'Riociguat'
         </a>
         below and
         <a class="local">
          'Other oral options'
         </a>
         below.)
        </p>
        <p>
         Oral therapy is rarely administered as a bridge to surgery since most patients with this indication are severely ill. (See
         <a class="local">
          'WHO functional class IV (severe symptoms)'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3957502075">
         <span class="h4">
          Riociguat
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         in patients with inoperable CTEPH and WHO functional class II to III  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ) have reported improved exercise capacity and pulmonary hemodynamics [
         <a href="#rid10">
          10,11,19-22
         </a>
         ].
        </p>
        <p>
         Best illustrating this is a multicenter, randomized, placebo-controlled trial (CHEST-1) that studied 261 patients with inoperable CTEPH (189 patients) or persistent PH following PTE (72 patients) [
         <a href="#rid10">
          10
         </a>
         ]. At 16 weeks, compared with placebo, patients on
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         (0.5 to 2.5 mg three times daily) had an improved six-minute walking distance (6MWD; increased by 39 m versus decreased by 6 m), and pulmonary vascular resistance (PVR; decreased by 226 dynes-sec/cm
         <sup>
          -5
         </sup>
         [2.8 Wood units] versus increased by 23 dynes-sec/cm
         <sup>
          -5
         </sup>
         [0.28 Wood units]). Outcomes were similar when a prespecified analysis was performed in the subgroup of patients with persistent CTEPH. Riociguat had a favorable safety profile with no reported difference between the two most common adverse events, which were right ventricular failure (3 percent) and syncope (2 to 3 percent).
        </p>
        <p>
         A follow-up long-term extension study (CHEST-2) reported that prolonged therapy for up to two years with
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         resulted in a similar efficacy and safety profile [
         <a href="#rid11">
          11,22
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3320510424">
         <span class="h4">
          Other oral options
         </span>
         <span class="headingEndMark">
          —
         </span>
         Small, randomized trials and observational data support improved exercise capacity and pulmonary hemodynamics in patients with CTEPH receiving ERAs and phosphodiesterase-5 inhibitors:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          ERAs
         </strong>
         – Several small studies in patients with CTEPH have shown that the ERAs, particularly oral
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         , improve physiologic parameters, symptoms and/or exercise capacity [
         <a href="#rid9">
          9,17,23-25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          Bosentan
         </a>
         – A systematic review of 10 observational studies and 1 randomized trial (BENEFiT) reported that bosentan resulted in a baseline increase in exercise capacity as measured by 6MWD (weighted mean difference [WMD] 35.9 meters, 95% CI 33.6-38.2 meters), a decrease in pulmonary artery pressure (WMD 2.62 mmHg, 95% CI 2.44-2.8), and an increase in cardiac index (WMD 0.23 L/min/m
         <sup>
          2
         </sup>
         , 95% CI 0.22-0.25 L/min/m
         <sup>
          2
         </sup>
         ) [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         In the only randomized placebo-controlled trial (BENEFiT) of 157 patients with inoperable CTEPH or persistent CTEPH after thromboendarterectomy who had WHO functional class II to IV, 16 weeks of
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         improved PVR and cardiac index compared with placebo [
         <a href="#rid9">
          9
         </a>
         ]. The same benefit was seen in the subgroup of patients with persistent CTEPH. However, there was no improvement in exercise capacity with bosentan.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="91206" href="/z/d/drug information/91206.html" rel="external">
          Macitentan
         </a>
         <strong>
         </strong>
         – The safety and feasibility of macitentan in improving the PVR and 6MWD in patients with inoperable CTEPH has also been reported [
         <a href="#rid17">
          17,25
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <a class="drug drug_general" data-topicid="8653" href="/z/d/drug information/8653.html" rel="external">
          Ambrisentan
         </a>
         – The Amber 1 trial compared ambrisentan with placebo in 33 patients with inoperable CTEPH. Although the study was terminated early due to futility of enrollment, positive trends in 6MWD, PVR, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) were noted [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Phosphodiesterase-5 inhibitors (
         </strong>
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         <strong>
          ,
         </strong>
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         <strong>
          )
         </strong>
         – In a randomized trial of 19 patients with inoperable CTEPH, 12 weeks of sildenafil improved WHO functional class and PVR, but there was no difference in exercise capacity, compared with placebo [
         <a href="#rid26">
          26
         </a>
         ]. The control patients were then provided open-label sildenafil. At 12 months, all patients had improved exercise capacity, symptom score, and PVR compared with baseline. Other nonrandomized trials support these results [
         <a href="#rid26">
          26-29
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         Preliminary data have suggested that
         <a class="drug drug_general" data-topicid="106041" href="/z/d/drug information/106041.html" rel="external">
          selexipag
         </a>
         is well tolerated and improves PVR in patients with inoperable or persistent CTEPH [
         <a href="#rid30">
          30
         </a>
         ]. Further data are needed before it can be used routinely.
        </p>
        <p class="headingAnchor" id="H1578322471">
         <span class="h3">
          Dual versus monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         We typically start with monotherapy (most often
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         ) and escalate to combination therapy (dual or triple therapy), if there is limited or no response to a single agent.
        </p>
        <p>
         Unlike patients in group 1 PAH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ) in whom benefit has been shown for initiating dual therapy, it is unknown if a similar approach benefits patients with CTEPH (group 4 PH). In one study, survival for up to five years in patients treated with combination therapy was similar to patients treated with monotherapy [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         When combination therapy is administered, we ensure that agents of the same class are not coadministered and that
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         is not coadministered with a phosphodiesterase inhibitor (eg,
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         ,
         <a class="drug drug_general" data-topicid="10108" href="/z/d/drug information/10108.html" rel="external">
          tadalafil
         </a>
         ), in order to avoid severe hypotension. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Combination oral therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H777220323">
         <span class="h2">
          WHO functional class IV (severe symptoms)
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who have WHO functional class IV and sometimes patients with severe functional class III  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ), we typically use a parenteral prostanoid (eg, intravenous
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         and intravenous or subcutaneous
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         )  (
         <a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">
          table 1
         </a>
         ). This preference is based upon the proven efficacy and extensive clinical experience with these agents in patients with group 1 PAH and limited observational data in the CTEPH population  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ). If response to monotherapy is suboptimal, we use a parenteral prostanoid-containing combination regimen (two or three drugs from a different class). On rare occasions for patients with a dramatic response to combination therapy, we attempt to wean the parenteral agent. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1223479832">
         <span class="h3">
          Parenteral prostanoid
         </span>
         <span class="headingEndMark">
          —
         </span>
         A small number of studies report benefit from prostanoids for patients with inoperable CTEPH [
         <a href="#rid27">
          27,32-38
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous
         </strong>
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         – A retrospective cohort study evaluated the effects of epoprostenol in 27 patients with inoperable CTEPH and WHO functional class III to IV  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ]. Three months of therapy with epoprostenol improved the PVR, pulmonary artery pressure, and exercise capacity. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Data in patients with CTEPH who received
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         as a bridge to PTE are limited. In one retrospective case series, 12 patients with severe CTEPH (defined as a PVR &gt;1200 dynes-sec/cm
         <sup>
          5
         </sup>
         ) who were treated with epoprostenol for a mean of 46 days prior to PTE had a 28 percent decrease in PVR preoperatively compared with baseline [
         <a href="#rid14">
          14
         </a>
         ]. Patients who received preoperative epoprostenol had a higher postoperative mortality compared with a group of patients who did not receive medical therapy preoperatively. The latter may be explained by the fact that untreated patients had milder disease. Nonetheless, these results also suggest that PH-specific therapy is not indicated for routine pre-operative care. Further trials in this population are pending.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Subcutaneous
         </strong>
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         – In a randomized trial of patients with inoperable, persistent, or recurrent CTEPH, and who had class III or IV symptoms, high-dose subcutaneous treprostinil (target dose 30 ng/kg/minute) resulted in improved 6MWD compared with a low-dose strategy (target dose 3 ng/kg/minute; increased by 45 meters versus 4.3 meters) [
         <a href="#rid39">
          39
         </a>
         ]. The adverse effects were similar in both groups and were mostly site-related reactions (eg, pain, redness, swelling). (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In an uncontrolled trial of 28 patients with severe inoperable CTEPH, subcutaneous
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         improved the PVR and was associated with five-year survival rate of 53 percent compared with 16 percent among historical controls [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled
         </strong>
         <a class="drug drug_general" data-topicid="8895" href="/z/d/drug information/8895.html" rel="external">
          iloprost
         </a>
         – One trial randomly assigned 203 patients with WHO class II to IV PH, 57 of whom had inoperable CTEPH, to receive inhaled iloprost or placebo for 12 weeks [
         <a href="#rid36">
          36
         </a>
         ]. Inhaled iloprost improved exercise capacity, functional class, pulmonary hemodynamics, symptoms, and quality of life. While the beneficial effect of inhaled iloprost in CTEPH is supported by additional studies, the high frequency of its administration (six to nine times per day) often discourages its use [
         <a href="#rid27">
          27,37,38
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhaled
         </strong>
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         – One study reported that the effect of inhaled treprostinil in combination with
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         in patients with CTEPH was similar to that in patients with PAH [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3736344998">
         <span class="h3">
          Combination dual or triple therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients who are refractory to or progress rapidly on monotherapy, we add a second or a third agent from a different class to a parenteral prostanoid. Phosphodiesterase inhibitors and guanylate cyclase stimulants should not be coadministered, due to harm from hypotension.
        </p>
        <p class="headingAnchor" id="H3715521052">
         <span class="h1">
          ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pulmonary hypertension (PH)-specific therapy should only be administered by a PH specialist. Initiation and escalation of therapy are similar to that in patients with group 1 pulmonary arterial hypertension (PAH)  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Nonvasoreactive patients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3048321593">
         <span class="h1">
          FOLLOW UP
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not responsive to, do not tolerate, or decline pulmonary hypertension (PH)-specific therapy, the selection of alternative or additional agents and treatment of refractory patients are similar to that of patients with group 1 pulmonary arterial hypertension (PAH). In addition, some patients may be candidates for balloon pulmonary angioplasty. These details are provided separately. (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Follow-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Refractory patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16637.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Initial management and evaluation for pulmonary artery thromboendarterectomy", section on 'Percutaneous balloon pulmonary angioplasty'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2191411340">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/115503.html" rel="external">
          "Society guideline links: Pulmonary hypertension in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16600277">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition
         </strong>
         <strong>
          and context
         </strong>
         - Surgical pulmonary thromboendarterectomy (PTE) is the only potentially curative therapy for patients with chronic thromboembolic pulmonary hypertension (CTEPH). However, a limited number of patients with CTEPH are treated with pulmonary hypertension (PH)-specific therapy. PH-specific therapy refers to the use of pulmonary vasodilators and remodeling agents to lower the pulmonary vascular resistance (PVR) and pulmonary artery pressure, thereby improving symptoms and signs such as exercise capacity and oxygenation. The benefits of PH-specific therapy are modest compared with those that can be achieved with surgery. Indications and recommendations for PTE are provided separately. (See
         <a class="local">
          'Introduction'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8255.html" rel="external">
          "Chronic thromboembolic pulmonary hypertension: Pulmonary thromboendarterectomy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient selection
         </strong>
         - In patients with CTEPH, the two most common indications for PH-specific therapy are patients with inoperable CTEPH and patients with a suboptimal hemodynamic and functional outcome following PTE (or balloon angioplasty). The use of PH-specific therapy as a bridge to PTE is an uncommon indication that is reserved for patients with severe or immediately life-threatening PH and right heart failure. (See
         <a class="local">
          'Patient selection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Medication selection
         </strong>
         - PH-specific therapy should
         <strong>
          only
         </strong>
         be administered at specialized PH centers. The principles of agent selection, administration, and follow-up of patients with CTEPH (group 4 PH) who receive PH-specific therapy are similar to that of patients with group 1 pulmonary arterial hypertension (PAH)  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         and
         <a class="graphic graphic_table graphicRef50798" href="/z/d/graphic/50798.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_table graphicRef123026" href="/z/d/graphic/123026.html" rel="external">
          table 5
         </a>
         and
         <a class="graphic graphic_table graphicRef123025" href="/z/d/graphic/123025.html" rel="external">
          table 4
         </a>
         ). However, patients with CTEPH do not need vasoreactivity testing and, for those in whom oral medications are indicated,
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         is the drug of choice. (See
         <a class="local">
          'Medication selection'
         </a>
         above and
         <a class="local">
          'Pre-treatment evaluation'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Pretreatment evaluation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with CTEPH rarely present with World Health Organization (WHO) functional class I  (
         <a class="graphic graphic_table graphicRef62080" href="/z/d/graphic/62080.html" rel="external">
          table 3
         </a>
         ) since patients in this class are typically asymptomatic or minimally symptomatic. Not everyone in this category may need therapy. The decision to initiate PAH-specific therapy in this population should be based on objective hemodynamic parameters to avoid ongoing progression of PH and personal preference. For those who do not receive or decline therapy, we closely observe for PH progression. (See
         <a class="local">
          'WHO class I (asymptomatic or minimally symptomatic)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For most patients who are not severely ill (ie, WHO functional class II or III), we suggest initiating oral
         <a class="drug drug_general" data-topicid="91067" href="/z/d/drug information/91067.html" rel="external">
          riociguat
         </a>
         rather than other agents (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This approach is based upon one randomized trial and several observational studies that report improved exercise capacity and pulmonary hemodynamics in patients with inoperable or persistent CTEPH who receive riociguat. Reasonable alternatives for oral therapy include
         <a class="drug drug_general" data-topicid="9254" href="/z/d/drug information/9254.html" rel="external">
          bosentan
         </a>
         or
         <a class="drug drug_general" data-topicid="9643" href="/z/d/drug information/9643.html" rel="external">
          sildenafil
         </a>
         based upon their favorable hemodynamic and safety profiles in patients with CTEPH. In most patients we initiate monotherapy and add in a second or third agent if symptoms progress. (See
         <a class="local">
          'WHO class II or III (mild to moderate symptoms)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are severely ill (ie, WHO functional class IV and, occasionally patients with severe class III symptoms or rapidly progressive disease), we suggest initiating a parenteral prostanoid (intravenous
         <a class="drug drug_general" data-topicid="9411" href="/z/d/drug information/9411.html" rel="external">
          epoprostenol
         </a>
         or
         <a class="drug drug_general" data-topicid="10207" href="/z/d/drug information/10207.html" rel="external">
          treprostinil
         </a>
         ) rather than an alternative agent (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). This preference is based upon the proven efficacy and extensive clinical experience with these agents in patients with group 1 PAH and limited data in CTEPH patients. (See
         <a class="local">
          'WHO functional class IV (severe symptoms)'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are refractory to monotherapy or progress rapidly despite therapy, we add a second or a third agent in a different class. Phosphodiesterase inhibitors and guanylate cyclase stimulants should not be coadministered, due to harm from hypotension. (See
         <a class="local">
          'Dual versus monotherapy'
         </a>
         above and
         <a class="local">
          'Combination dual or triple therapy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Follow-up
         </strong>
         - Initiation, follow-up, and escalation of PH-specific therapy and treatment of refractory patients with CTEPH are similar to that in patients with group 1 PAH  (
         <a class="graphic graphic_table graphicRef66348" href="/z/d/graphic/66348.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Nonvasoreactive patients'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Follow-up'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/8250.html" rel="external">
          "Treatment of pulmonary arterial hypertension (group 1) in adults: Pulmonary hypertension-specific therapy", section on 'Refractory patients'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Fedullo P, Kerr KM, Kim NH, Auger WR. Chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2011; 183:1605.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Piazza G, Goldhaber SZ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2011; 364:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim NH, Delcroix M, Jais X, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2019; 53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kim NH, Delcroix M, Jenkins DP, et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62:D92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delcroix M, Torbicki A, Gopalan D, et al. ERS statement on chronic thromboembolic pulmonary hypertension. Eur Respir J 2021; 57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2022; 43:3618.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Perrot M, Gopalan D, Jenkins D, et al. Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT. J Heart Lung Transplant 2021; 40:1301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen KW, Kerr KM, Fedullo PF, et al. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. Circulation 2009; 120:1248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaïs X, D'Armini AM, Jansa P, et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52:2127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghofrani HA, D'Armini AM, Grimminger F, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369:319.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonneau G, D'Armini AM, Ghofrani HA, et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cannon JE, Su L, Kiely DG, et al. Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort. Circulation 2016; 133:1761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hsieh WC, Jansa P, Huang WC, et al. Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis. J Thorac Cardiovasc Surg 2018; 156:1275.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nagaya N, Sasaki N, Ando M, et al. Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension. Chest 2003; 123:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Condliffe R, Kiely DG, Gibbs JS, et al. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2008; 177:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulrich S, Fischler M, Speich R, et al. Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties. Chest 2006; 130:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghofrani HA, Simonneau G, D'Armini AM, et al. Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study. Lancet Respir Med 2017; 5:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Escribano-Subias P, Bendjenana H, Curtis PS, et al. Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH). Pulm Circ 2019; 9:2045894019846433.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010; 36:792.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frey R, Mück W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008; 48:926.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wardle AJ, Seager MJ, Wardle R, et al. Guanylate cyclase stimulators for pulmonary hypertension. Cochrane Database Syst Rev 2016; :CD011205.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Simonneau G, D'Armini AM, Ghofrani HA, et al. Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial. Lancet Respir Med 2016; 4:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006; 28:138.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becattini C, Manina G, Busti C, et al. Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis. Thromb Res 2010; 126:e51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Thor MCJ, Ten Klooster L, Snijder RJ, et al. Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension? Lung 2019; 197:753.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suntharalingam J, Treacy CM, Doughty NJ, et al. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. Chest 2008; 134:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136:515.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghofrani HA, Schermuly RT, Rose F, et al. Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2003; 167:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reichenberger F, Voswinckel R, Enke B, et al. Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J 2007; 30:922.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ogo T, Shimokawahara H, Kinoshita H, et al. Selexipag for the treatment of chronic thromboembolic pulmonary hypertension. Eur Respir J 2022; 60.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Thor MCJ, Snijder RJ, Kelder JC, et al. Does combination therapy work in chronic thromboembolic pulmonary hypertension? Int J Cardiol Heart Vasc 2020; 29:100544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bresser P, Fedullo PF, Auger WR, et al. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McLaughlin VV, Genthner DE, Panella MM, et al. Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series. Ann Intern Med 1999; 130:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabrol S, Souza R, Jais X, et al. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant 2007; 26:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skoro-Sajer N, Bonderman D, Wiesbauer F, et al. Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension. J Thromb Haemost 2007; 5:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olschewski H, Simonneau G, Galiè N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347:322.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramm T, Eberle B, Krummenauer F, et al. Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy. Ann Thorac Surg 2003; 76:711.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krug S, Hammerschmidt S, Pankau H, et al. Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension. Respiration 2008; 76:154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghofrani HA. Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension? Lancet Respir Med 2019; 7:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voswinckel R, Reichenberger F, Enke B, et al. Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension. Pulm Pharmacol Ther 2008; 21:824.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 16628 Version 37.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21330453" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21268727" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30545969" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24355646" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33334946" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : ERS statement on chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36017548" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34420851" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Evaluation and management of patients with chronic thromboembolic pulmonary hypertension - consensus statement from the ISHLT.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19752321" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19095129" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23883377" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25395036" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27052413" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Dynamic Risk Stratification of Patient Long-Term Outcome After Pulmonary Endarterectomy: Results From the United Kingdom National Cohort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29903403" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Residual pulmonary hypertension after pulmonary endarterectomy: A meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12576349" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prostacyclin therapy before pulmonary thromboendarterectomy in patients with chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18292468" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16963684" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28919201" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1): results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30957635" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Ambrisentan for treatment of inoperable chronic thromboembolic pulmonary hypertension (CTEPH).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20530034" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519919" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27482837" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Guanylate cyclase stimulators for pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27067478" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16611652" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20172593" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Bosentan for chronic thromboembolic pulmonary hypertension: findings from a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31583452" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Bosentan or Macitentan Therapy in Chronic Thromboembolic Pulmonary Hypertension?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263674" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11926786" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12684251" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17690123" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34824052" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32518816" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Does combination therapy work in chronic thromboembolic pulmonary hypertension?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15083760" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10357693" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Compassionate use of continuous prostacyclin in the management of secondary pulmonary hypertension: a case series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17403477" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17319903" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Treprostinil for severe inoperable chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12151469" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Inhaled iloprost for severe pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12963183" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17804899" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Acute improved hemodynamics following inhaled iloprost in chronic thromboembolic pulmonary hypertension.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30477764" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Subcutaneous treprostinil: a new treatment for chronic thromboembolic pulmonary hypertension?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18657627" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Acute effects of the combination of sildenafil and inhaled treprostinil on haemodynamics and gas exchange in pulmonary hypertension.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
